MNG1263
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.299
- KRAS_SIGNALING_DN+0.285
- MYOGENESIS+0.278
- APICAL_SURFACE+0.232
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.182
- WNT_BETA_CATENIN_SIGNALING+0.175
- PANCREAS_BETA_CELLS+0.169
- APICAL_JUNCTION+0.162
- PEROXISOME+0.118
- OXIDATIVE_PHOSPHORYLATION+0.064
Top 10 suppressed
- G2M_CHECKPOINT-0.460
- PROTEIN_SECRETION-0.431
- TNFA_SIGNALING_VIA_NFKB-0.425
- E2F_TARGETS-0.412
- MTORC1_SIGNALING-0.367
- INFLAMMATORY_RESPONSE-0.327
- MYC_TARGETS_V1-0.300
- MITOTIC_SPINDLE-0.276
- ANGIOGENESIS-0.263
- IL6_JAK_STAT3_SIGNALING-0.216
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1403222 | GTEX | — | 0.798 |
| 2 | SRR1380680 | GTEX | — | 0.765 |
| 3 | SJEPD019_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.760 |
| 4 | SRR6079989 | — | — | 0.749 |
| 5 | MNG559 | — | — | 0.748 |
| 6 | SRR1316815 | GTEX | — | 0.747 |
| 7 | SRR1476279 | GTEX | — | 0.731 |
| 8 | SRR1471773 | GTEX | — | 0.726 |
| 9 | SRR1391922 | GTEX | — | 0.724 |
| 10 | f17e12f0-54ed-4dc2-ab7e-22a1f90e1405 | — | — | 0.723 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.299 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.285 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.278 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.232 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.182 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.175 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.169 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.162 | Inavolisib | — uncovered |
| PEROXISOME | 0.118 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.064 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.029 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.027 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.013 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.009 | Inavolisib | — uncovered |
| COAGULATION | 0.006 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.005 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.001 | Idelalisib | — uncovered |